WJV  Vol.3 No.4 , November 2013
Protection by Recombinant Newcastle Disease Viruses (NDV) Expressing the Glycoprotein (G) of Avian Metapneumovirus (aMPV) Subtype A or B against Challenge with Virulent NDV and aMPV
Abstract: Avian metapneumovirus (aMPV) and Newcastle disease virus (NDV) are threatening avian pathogens that can cause serious respiratory diseases in poultry worldwide. Vaccination, combined with strict biosecurity practices, has been the recommendation for controlling these diseases in the field. In the present study, we generated NDV LaSota vaccine strain-based recombinant viruses expressing the glycoprotein (G) of aMPV, subtype A or B, using reverse genetics technology. These recombinant viruses, rLS/aMPV-A G and rLS/aMPV-B G, were characterized in cell cultures and evaluated in turkeys as bivalent, next-generation vaccines. The results showed that these recombinant vaccine candi-dates were slightly attenuated in vivo, yet maintained similar growth dynamics, cytopathic effects, and virus titers in vitro when compared to the parental LaSota virus. The expression of the aMPV G protein in recombinant virus-infected cells was detected by immunofluorescence. Vaccination of turkeys with rLS/aMPV-A G or rLS/aMPV-B G conferred complete protection against velogenic NDV, CA02 strain challenge and partial protection against homologous patho-genic aMPV challenge. These results suggest that the LaSota recombinant virus is a safe and effective vaccine vector and expression of the G protein alone is not sufficient to provide full protection against aMPV-A or -B infections. Ex-pression of other aMPV-A or -B virus immunogenic protein(s) individually or in conjunction with the G protein may be necessary to induce stronger and more protective immunity against aMPV diseases.
Cite this paper: Q. Yu, J. Roth, H. Hu, C. Estevez, W. Zhao and L. Zsak, "Protection by Recombinant Newcastle Disease Viruses (NDV) Expressing the Glycoprotein (G) of Avian Metapneumovirus (aMPV) Subtype A or B against Challenge with Virulent NDV and aMPV," World Journal of Vaccines, Vol. 3 No. 4, 2013, pp. 130-139. doi: 10.4236/wjv.2013.34018.

[1]   J. K. Cook, “Avian Pneumovirus Infections of Turkeys and Chickens,” Veterinary Journal, Vol.160, No.2, 2000, pp.118-125.

[2]   R. E. Gough and R. C. Jones, “Avian Metapneumovirus,” In: Y. M. Saif, A. M. Fadly, J. R. Glisson, L. R. McDougald, L. K. Nolan and D. E. Swayne, Eds., Diseases of Poultry, Blackwell Publishing, Ames, 2008, pp.100-110.

[3]   E. Lee, M. S. Song, J. Y. Shin, Y. M. Lee, C. J. Kim, Y. S. Lee, H. Kim and Y. K. Choi, “Genetic Characterization of Avian Metapneumovirus Subtype C Isolated from Pheasants in a Live Bird Market,” Virus Research, Vol. 128, No. 1-2, 2007, pp. 18-25.

[4]   D. Toquin, O. Guionie, V. Jestin, F. Zwingelstein, C. Allee and N. Eterradossi, “European and American Subgroup C Isolates of Avian Metapneumovirus Belong to Different Genetic Lineages,” Virus Genes, Vol. 32, No. 1, 2006, pp. 97-103.

[5]   M. H. Bayon-Auboyer, C. Arnauld, D. Toquin and N. Eterradossi, “Nucleotide Sequences of the F, L and G Protein Genes of Two Non-A/Non-B Avian Pneumoviruses (APV) Reveal a Novel APV Subgroup,” Journal of General Virology, Vol. 81, No. 11, 2000, pp. 2723-2733.

[6]   J. K. Cook, F. Orthel, S. Orbell, M. A. Woods and M. B. Huggins, “An Experimental Turkey Rhinotracheitis (TRT) Infection in Breeding Turkeys and the Prevention of Its Clinical Effects Using Live-Attenuated and Inactivated TRT Vaccines,” Avian Pathology, Vol. 25, No. 2, 1996, pp. 231-243.

[7]   K. Ganapathy, A. Bufton, A. Pearson, S. Lemiere and R. C. Jones, “Vaccination of Commercial Broiler Chicks against Avian Metapneumovirus Infection: A Comparison of Drinking-Water, Spray and Oculo-Oral Delivery Methods,” Vaccine, Vol. 28, No. 23, 2010, pp. 3944-3948.

[8]   R. C. Jones, “Viral Respiratory Diseases (ILT, aMPV Infections, IB): Are They Ever under Control?” British Poultry Science, Vol. 51, No. 1, 2010, pp. 1-11.

[9]   P. A. Brown, C. Lupini, E. Catelli, J. Clubbe, E. Ricchizzi and C. J. Naylor, “A Single Polymerase (L) Mutation in Avian Metapneumovirus Increased Virulence and Partially Maintained Virus Viability at an Elevated Temperature,” Journal of General Virology, Vol. 92, No. 2, 2011, pp. 346-354.

[10]   E. Catelli, M. Cecchinato, C. E. Savage, R. C. Jones and C. J. Naylor, “Demonstration of Loss of Attenuation and Extended Field Persistence of a Live Avian Metapneumovirus Vaccine,” Vaccine, Vol. 24, No. 42-43, 2006, pp. 6476-6482.

[11]   E. Catelli, C. Lupini, M. Cecchinato, E. Ricchizzi, P. A. Brown and C. J. Naylor, “Field Avian Metapneumovirus Evolution Avoiding Vaccine Induced Immunity,” Vaccine, Vol. 28, No. 4, 2010, pp. 916-921.

[12]   M. Cecchinato, E. Catelli, C. Lupini, E. Ricchizzi, J. Clubbe, M. Battilani and C. J. Naylor, “Avian Metapneumovirus (AMPV) Attachment Protein Involvement in Probable Virus Evolution Concurrent with Mass Live Vaccine Introduction,” Veterinary Microbiology, Vol. 146, No. 1-2, 2010, pp. 24-34.

[13]   J. L. Chacon, M. Mizuma, M. P. Vejarano, D. Toquin, N. Eterradossi, D. P. Patnayak, S. M. Goyal and A. J. Fer- reira, “Avian Metapneumovirus Subtypes Circulating in Brazilian Vaccinated and Nonvaccinated Chicken and Turkey Farms,” Avian Diseases, Vol. 55, No. 1, 2011, pp. 82-89.

[14]   R. M. Cha, M. Khatri and J. M. Sharma, “Protection against Avian Metapneumovirus Subtype C in Turkeys Immunized via the Respiratory Tract with Inactivated Virus,” Vaccine, Vol. 29, No. 3, 2011, pp. 459-465.

[15]   P. Chary, M. K. Njenga and J. M. Sharma, “Protection by Recombinant Viral Proteins against a Respiratory Challenge with Virulent Avian Metapneumovirus,” Veterinary Immunology and Immunopathology, Vol. 108, No. 3-4, 2005, pp. 427-432.

[16]   D. R. Kapczynski, “Development of a Virosome Vaccine against Avian Metapneumovirus Subtype C for Protection in Turkeys,” Avian Diseases, Vol. 48, No. 2, 2004, pp. 332-343.

[17]   D. R. Kapczynski, L. L. Perkins and H. S. Sellers, “Mucosal Vaccination with Formalin-Inactivated Avian Metapneumovirus Subtype C Does Not Protect Turkeys Following Intranasal Challenge,” Avian Diseases, Vol. 52, No. 1, 2008, pp. 28-33.

[18]   D. R. Kapczynski and H. S. Sellers, “Immunization of Turkeys with a DNA Vaccine Expressing Either the F or N Gene of Avian Metapneumovirus,” Avian Diseases, Vol. 47, No. 4, 2003, pp. 1376-1383.

[19]   C. J. Naylor, R. Ling, N. Edworthy, C. E. Savage and A. J. Easton, “Avian Metapneumovirus SH Gene End and G Protein Mutations Influence the Level of Protection of Li- ve-Vaccine Candidates,” Journal of General Virology, Vol. 88, No. 6, 2007, pp. 1767-1775.

[20]   C. J. Naylor, C. Lupini and P. A. Brown, “Charged Ami- no Acids in the AMPV Fusion Protein Have More Influence on Induced Protection than Deletion of the SH or G Genes,” Vaccine, Vol. 28, No. 41, 2010, pp. 6800-6807.

[21]   Y. Qingzhong, T. Barrett, T. D. Brown, J. K. Cook, P. Green, M. A. Skinner and D. Cavanagh, “Protection against Turkey Rhinotracheitis Pneumovirus (TRTV) Induced by a Fowlpox Virus Recombinant Expressing the TRTV Fusion Glycoprotein (F),” Vaccine, Vol. 12, No. 6, 1994, pp. 569-573.

[22]   D. J. Alexander and D. A. Senne, “Newcastle Disease, Other Avian Paramyxoviruses, and Pneumovirus Infections,” In: Y. M. Saif, A. M. Fadly, J. R. Glisson, L. R. McDougald, L. K. Nolan and D. E. Swayne, Eds., Diseases of Poultry, Blackwell Publishing, Ames, 2008, pp. 75-100.

[23]   S. B. Hitchner, “History of Biological Control of Poultry Diseases in the USA,” Avian Diseases, Vol. 48, No. 1, 2004, pp. 1-8.

[24]   J. Ge, G. Deng, Z. Wen, G. Tian, Y. Wang, J. Shi, X. Wang, Y. Li, S. Hu, Y. Jiang, C. Yang, K. Yu, Z. Bu and H. Chen, “Newcastle Disease Virus-Based Live Attenuated Vaccine Completely Protects Chickens and Mice from Lethal Challenge of Homologous and Heterologous H5N1 Avian Influenza Viruses,” Journal of Virology, Vol. 81, No. 1, 2007, pp. 150-158.

[25]   Z. Huang, S. Elankumaran, A. S. Yunus and S. K. Samal, “A Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects against NDV and IBDV,” Journal of Virology, Vol. 78, No. 18, 2004, pp. 10054-10063.

[26]   B. Nayak, S. N. Rout, S. Kumar, M. S. Khalil, M. M. Fouda, L. E. Ahmed, K. C. Earhart, D. R. Perez, P. L. Collins and S. K. Samal, “Immunization of Chickens with Newcastle Disease Virus Expressing H5 Hemagglutinin Protects against Highly Pathogenic H5N1 Avian Influenza Viruses,” PLoS One, Vol. 4, No. 8, 2009, p. E6509.

[27]   M. S. Park, J. Steel, A. Garcia-Sastre, D. Swayne and P. Palese, “Engineered Viral Vaccine Constructs with Dual Specificity: Avian Influenza and Newcastle Disease,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 21, 2006, pp. 8203-8208.

[28]   J. Veits, D. Wiesner, W. Fuchs, B. Hoffmann, H. Granzow, E. Starick, E. Mundt, H. Schirrmeier, T. Mebatsion, T. C. Mettenleiter and A. Romer-Oberdorfer, “Newcastle Disease Virus Expressing H5 Hemagglutinin Gene Protects Chickens against Newcastle Disease and Avian Influenza,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 21, 2006, pp. 8197-8202.

[29]   Q. Yu, C. N. Estevez, M. Song, D. R. Kapczynski and L. Zsak, “Generation and Biological Assessment of Recombinant Avian Metapneumovirus Subgroup C (aMPV-C) Viruses Containing Different Length of the G Gene,” Virus Research, Vol. 147, No. 2, 2010, pp. 182-188.

[30]   H. Hu, J. P. Roth, C. N. Estevez, L. Zsak, B. Liu and Q. Yu, “Generation and Evaluation of a Recombinant Newcastle Disease Virus Expressing the Glycoprotein (G) of Avian Metapneumovirus Subgroup C as a Bivalent Vaccine in Turkeys,” Vaccine, Vol. 29, No. 47, 2011, pp. 8624-8633.

[31]   C. N. Estevez, D. J. King, B. Seal and Q. Yu, “Evaluation of Newcastle Disease Virus Chimeras Expressing the Hemagglutinin-Neuraminidase Protein of Velogenic Strains in the Context of a Mesogenic Recombinant Virus Backbone,” Virus Research, Vol.129, No.2, 2007, pp.182-190.

[32]   D. J. Alexander, “Newcastle Disease Virus and Other Avian Paramyxoviruses,” In: D. Swayne, J. R. Glisson, M. W. Jackwood, J. E. Pearson and W. M. Reed, Eds., A Laboratory Manual for the Isolation and Identification of Avian Pathogens, American Association of Avian Pathologists, Kennett Square, 1998, pp.156-163.

[33]   D. R. Kapczynski and D. J. King, “Protection of Chickens against Overt Clinical Disease and Determination of Viral Shedding Following Vaccination with Commercially Available Newcastle Disease Virus Vaccines upon Challenge with Highly Virulent Virus from the California 2002 Exotic Newcastle Disease Outbreak,” Vaccine, Vol. 23, No. 26, 2005, pp. 3424-3433.

[34]   J. K. Cook, M. M. Ellis, C. A. Dolby, H. C. Holmes, P. M. Finney and M. B. Huggins, “A Live Attenuated Turkey Rhinotracheitis Virus Vaccine: 1. Stability of the Attenuated Strain,” Avian Pathology, Vol.18, No.3, 1989, pp.511-522.

[35]   Q. Yu, C. N. Estevez, J. P. Roth, H. Hu and L. Zsak, “Deletion of the M2-2 Gene from Avian Metapneumovirus Subgroup C Impairs Virus Replication and Immunogenicity in Turkeys,” Virus Genes, Vol.42, No.3, 2011, pp.339-346.

[36]   D. Kolakofsky, L. Roux, D. Garcin and R. W. Ruigrok, “Paramyxovirus mRNA Editing, the ‘Rule of Six’ and Error Catastrophe: A Hypothesis,” Journal of General Virology, Vol. 86, No. 7, 2005, pp. 1869-1877.

[37]   D. Govindarajan, S. H. Kim and S. K. Samal, “Contribution of the Attachment G Glycoprotein to Pathogenicity and Immunogenicity of Avian Metapneumovirus Subgroup C,” Avian Diseases, Vol.54, No.1, 2010, pp.59-66.

[38]   R. C. Jones, C. Baxter-Jones, G. P. Wilding and D. F. Kelly, “Demonstration of a Candidate Virus for Turkey Rhinotracheitis in Experimentally Inoculated Turkeys,” Veterinary Record, Vol.119, No.24, 1986, pp.599-600.